Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults with Severe Immunoglobulin E (IgE)-Mediated Food Allergy

End 11 Aug 2025 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol R5458-668-ALG-2219

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other

Status Ended

Participants planned 9

Countries 1

Sites 2

Severe IgE-mediated food allergy

Key facts

Sponsor: Regeneron Pharmaceuticals Inc.
Participant type: Patients
Age range: 18-64 years
Gender: Male and Female
Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trial duration: completed 11 Aug 2025
Decision date (initial): 2024-06-11
Transition trial: No
Low-intervention: No
Rare-disease indication: No
Vulnerable population: No

External identifiers

EU CT number: 2024-511032-27-00
ClinicalTrials.gov: NCT06369467

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Severe IgE-mediated food allergy

Version	Level	Code	Term	System organ class
20.0	PT	10016946	Food allergy	100000004870

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Regeneron Pharmaceuticals Inc.

Sponsor organisation: Regeneron Pharmaceuticals Inc.
Address: 777 Old Saw Mill River Road
City: Tarrytown
Postcode: 10591-6717
Country: United States

Scientific contact point

Organisation: Regeneron Pharmaceuticals Inc.
Contact name: Medical Affairs

Public contact point

Organisation: Regeneron Pharmaceuticals Inc.
Contact name: Medical Affairs

Locations

1 EU/EEA country · 2 investigational sites

By country

Country	MS status	Planned subjects	Sites
Spain	Ended	3	2
Rest of world United States	—	6	—

Investigational sites

Spain

2 sites · Ended

Clinica Universidad De Navarra

Allergy and Immunology, Avenue Pio XII 36, 31008, Pamplona